IRIS
GOZZETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.063
EU - Europa 12.023
AS - Asia 7.837
SA - Sud America 1.625
AF - Africa 352
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 11
Totale 38.926
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.827
RU - Federazione Russa 2.643
SG - Singapore 2.565
CN - Cina 2.502
GB - Regno Unito 2.339
IE - Irlanda 1.685
IT - Italia 1.494
BR - Brasile 1.343
UA - Ucraina 860
VN - Vietnam 856
FR - Francia 800
SE - Svezia 800
HK - Hong Kong 629
DE - Germania 575
FI - Finlandia 379
KR - Corea 343
IN - India 190
ZA - Sudafrica 159
BD - Bangladesh 154
CA - Canada 127
NL - Olanda 100
TR - Turchia 99
AR - Argentina 94
IQ - Iraq 84
NG - Nigeria 66
JP - Giappone 64
MX - Messico 64
PL - Polonia 59
ID - Indonesia 51
ES - Italia 47
EC - Ecuador 44
AT - Austria 41
BE - Belgio 36
MA - Marocco 33
SA - Arabia Saudita 32
CL - Cile 30
CO - Colombia 30
PK - Pakistan 30
UZ - Uzbekistan 30
VE - Venezuela 29
CZ - Repubblica Ceca 27
KE - Kenya 24
PY - Paraguay 23
LT - Lituania 22
IR - Iran 20
JO - Giordania 20
EG - Egitto 18
MY - Malesia 17
PE - Perù 17
NP - Nepal 16
AU - Australia 15
KZ - Kazakistan 15
RS - Serbia 15
TN - Tunisia 15
AZ - Azerbaigian 13
AE - Emirati Arabi Uniti 12
CH - Svizzera 12
CI - Costa d'Avorio 12
OM - Oman 12
AL - Albania 10
DZ - Algeria 10
JM - Giamaica 10
BO - Bolivia 9
DO - Repubblica Dominicana 9
IL - Israele 9
PH - Filippine 9
PT - Portogallo 9
TW - Taiwan 9
EE - Estonia 8
LB - Libano 8
PS - Palestinian Territory 8
TH - Thailandia 8
BG - Bulgaria 7
EU - Europa 7
KG - Kirghizistan 7
RO - Romania 7
DK - Danimarca 6
LV - Lettonia 6
SK - Slovacchia (Repubblica Slovacca) 6
TT - Trinidad e Tobago 6
AO - Angola 5
ET - Etiopia 5
GR - Grecia 5
PA - Panama 5
UY - Uruguay 5
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
LK - Sri Lanka 4
CR - Costa Rica 3
HN - Honduras 3
HR - Croazia 3
KH - Cambogia 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
NI - Nicaragua 3
NO - Norvegia 3
BB - Barbados 2
BH - Bahrain 2
CW - ???statistics.table.value.countryCode.CW??? 2
GE - Georgia 2
Totale 38.895
Salva come PNG Salva come JPEG
Città #
Fairfield 2.027
Southend 1.984
Dallas 1.954
Dublin 1.662
Singapore 1.360
Ashburn 1.257
Woodbridge 988
Chandler 810
Houston 785
Seattle 781
Wilmington 765
Moscow 737
Jacksonville 732
Santa Clara 696
Cambridge 638
Beijing 612
Hong Kong 610
San Jose 529
Hefei 424
Ann Arbor 409
Princeton 371
Seoul 339
Siena 325
The Dalles 292
Ho Chi Minh City 264
Nanjing 249
Los Angeles 240
Lauterbourg 220
Helsinki 196
Hanoi 187
Council Bluffs 177
Milan 152
Munich 136
New York 135
Johannesburg 132
San Mateo 132
São Paulo 125
Boardman 111
Buffalo 109
Florence 109
San Diego 107
Rome 90
Dong Ket 88
Shanghai 79
Nanchang 77
London 75
Orem 66
Abuja 63
Dearborn 63
Redondo Beach 56
Shenyang 56
Tokyo 51
Bengaluru 50
Menlo Park 50
Nuremberg 49
Hebei 48
Turku 48
Izmir 47
San Francisco 47
Columbus 46
Tianjin 46
Warsaw 45
Frankfurt am Main 44
Lappeenranta 41
Toronto 40
Jiaxing 38
Chicago 37
Stockholm 37
Denver 36
Kunming 36
Phoenix 35
Brussels 34
Da Nang 34
Baghdad 33
Montreal 32
Rio de Janeiro 32
Brooklyn 31
Changsha 29
Chennai 29
Atlanta 28
Tashkent 28
Belo Horizonte 27
Bologna 27
Curitiba 27
Dhaka 26
Turin 26
Zhengzhou 26
Haiphong 25
Norwalk 25
Mexico City 24
Brasília 23
Porto Alegre 23
Amsterdam 22
Boston 22
Guangzhou 22
Poplar 22
Portsmouth 21
Kilburn 20
Vienna 20
Amman 19
Totale 26.209
Salva come PNG Salva come JPEG
Nome #
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients 335
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 334
Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. 324
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 311
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 307
Preferential usage of specific immunoglobulin heavy chain variable region genes with unmutated profile and advanced stage at presentation are common features in patients with chronic lymphocytic leukemia from Senegal 296
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 292
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 291
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 289
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 288
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 288
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia 288
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 284
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 279
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 276
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 276
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 271
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) 271
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 269
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 263
Second generation proteasome inhibitors in multiple myeloma 258
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 256
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 251
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 251
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 250
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 248
Central nervous system multiple myeloma 244
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 242
EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma. 242
Sixth nerve and superior division of third nerve palsy due to intracranial extension of multiple myeloma. A diagnostic challenge and differential diagnosis 242
Adult lymphoblastic lymphoma: Clinical features and prognostic factors in 53 patients 234
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 232
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 231
A BRAF Negative Classic Hairy Cell Leukemia Patient in Long Lasting Complete Remission after Rituximab and Pentostatin 230
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 229
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 228
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 225
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 224
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 218
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 217
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 216
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 216
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network 215
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 212
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 212
FLT3 inhibitors in the management of acute myeloid leukemia 210
A case of bone lesion in a patient with relapsed chronic lymphocytic leukemia and review of the literature 209
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 209
Treatment of smoldering multiple myeloma 208
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 208
A novel t(6;7)(p24;q21) in a chronic myelocytic leuckemia in complete cytogenetic remission after therapy with imatinib mesylate 207
Daratumumab efficacy in extramedullary orbital myeloma 207
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors 204
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients 204
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group 203
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 202
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 202
Apoliprotein E-mediated ferroptosis controls cellular proliferation in chronic lymphocytic leukemia 201
Myelodysplasia presenting as thoracic spinal epidural extramedullary hematopoiesis: a rare treatable cause of spinal cord myelopathy 201
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 201
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 200
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol 198
An unusual presentation of chronic B-cell lymphocytic leukaemia 197
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 196
Allogeneic bone marrow transplantation for the treatment of multiple myeloma: An overview of published reports 195
Anti CD38 monoclonal antibodies for multiple myeloma treatment 195
Extramedullary myeloma relapses 194
Hyperlipidemia in a myeloma patient after bortezomib treatment 193
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 193
Evolving treatments in multiple myeloma patients with renal failure 192
Predicting the clinical course of Hodgkin lymphoma 191
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 189
The effects of zoledronic acid on serum lipids in multiple myeloma patients 189
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 189
Bcr-abl peptides for chronic myeloid leukemia. 188
Intracranial involvement in plasmacytomas and multiple myeloma: A pictorial essay 188
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 187
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice 186
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion 186
Fludarabine in patients with advanced and/or resistant B‐chronic lymphocytic leukemia 185
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 183
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma 181
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 179
Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region 179
Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma 179
Unusual localizations of plasmacytoma 178
Reply to “Rituximab activity in CD20-positive multiple myeloma” 177
Trisomy 13 in a patient with acute myeloid leukemia M0 and unusual durable remission 177
Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy 176
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 176
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network) 175
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 174
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study 172
Central Nervous System Multiple Myeloma 171
Speckle tracking echocardiography in plasma cell disorders: The role of advanced imaging in the early diagnosis of AL systemic cardiac amyloidosis 170
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 170
Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia 168
CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome 167
Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: A phase II study 167
Evidences of new risk factors for retinal vein thrombosis 167
Totale 22.048
Salva come PNG Salva come JPEG
Categoria #
all - tutte 130.101
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 130.101
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021283 0 0 0 0 0 0 0 0 0 0 0 283
2021/20222.432 160 250 172 176 93 99 125 91 125 285 275 581
2022/20233.256 239 225 436 474 281 673 87 246 296 46 187 66
2023/20242.452 105 57 225 133 67 609 846 48 20 68 39 235
2024/20255.856 172 294 555 319 647 372 158 333 479 347 641 1.539
2025/202613.299 1.066 2.034 1.551 1.858 2.423 544 1.332 365 591 713 555 267
Totale 39.540